Relationship between BRAFV600E mutation and metastasis after thyroidectomy in papillary thyroid carcinoma with different recurrence risk stratification

中华核医学与分子影像杂志 Pub Date : 2019-11-25 DOI:10.3760/CMA.J.ISSN.2095-2848.2019.11.004

Z. Jia, R. Yan, Chang-qing Zhang, H. Zhai, Tianzheng Yang, Zhenhu Zhou

{"title":"Relationship between BRAFV600E mutation and metastasis after thyroidectomy in papillary thyroid carcinoma with different recurrence risk stratification","authors":"Z. Jia, R. Yan, Chang-qing Zhang, H. Zhai, Tianzheng Yang, Zhenhu Zhou","doi":"10.3760/CMA.J.ISSN.2095-2848.2019.11.004","DOIUrl":null,"url":null,"abstract":"Objective \nTo investigate the relationship between V-raf murine sarcoma viral oncogene homologue B1 (BRAF)V600E mutation and metastasis after thyroidectomy in papillary thyroid carcinoma (PTC) with different recurrence risk stratification. \n \n \nMethods \nFrom March 2014 to September 2017, 134 PTC patients (45 males, 89 females; age: 16-72 years) who underwent 131I treatment in the Department of Nuclear Medicine of Liaocheng People′s Hospital and had undergone BRAFV600E mutation detection were retrospectively analyzed. The recurrence risk during surgery was divided into 3 levels: low-, medium- and high-risk. Each recurrence risk group was divided into 3 subgroups according to the postoperative follow-up results: non-metastasis group, cervical lymph node metastasis group and pulmonary metastasis group. BRAFV600E mutation rates in different groups were compared (χ2 test). \n \n \nResults \nThe BRAFV600E mutation rate was 55.22%(74/134) in 134 PTC patients. The mutation rates were not significantly different in the 3 metastasis subgroups for low-risk patients (n=46; χ2=2.39, P>0.05). In medium-risk patients (n=47), the mutation rate in neck lymph node metastasis group (16/19) was higher than that in pulmonary metastasis group (3/8) and non-metastasis group (25.00%, 5/20; χ2 values: 5.89 and 13.75, both P 0.05). In high risk patients (n=41), the mutation rate in neck lymph node metastasis group (85.00%, 17/20) was higher than that in the pulmonary metastasis group (5/13) and non-metastasis group (1/8; χ2 values: 7.68 and 13.08, both P 0.05). \n \n \nConclusion \nThe BRAFV600E mutation is closely related to neck lymph node metastasis after operation in middle- and high-risk patients with PTC, but it does not significantly increase the probabilities of neck lymph node metastasis in low-risk patients and pulmonary metastasis in low-, medium- and high-risk patients. \n \n \nKey words: \nThyroid neoplasms; Neoplasms recurrence, local; Neoplasm metastasis; Proto-oncogene protein B-raf; Mutation","PeriodicalId":10099,"journal":{"name":"中华核医学与分子影像杂志","volume":"39 1","pages":"657-660"},"PeriodicalIF":0.0000,"publicationDate":"2019-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中华核医学与分子影像杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.2095-2848.2019.11.004","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Objective To investigate the relationship between V-raf murine sarcoma viral oncogene homologue B1 (BRAF)V600E mutation and metastasis after thyroidectomy in papillary thyroid carcinoma (PTC) with different recurrence risk stratification. Methods From March 2014 to September 2017, 134 PTC patients (45 males, 89 females; age: 16-72 years) who underwent 131I treatment in the Department of Nuclear Medicine of Liaocheng People′s Hospital and had undergone BRAFV600E mutation detection were retrospectively analyzed. The recurrence risk during surgery was divided into 3 levels: low-, medium- and high-risk. Each recurrence risk group was divided into 3 subgroups according to the postoperative follow-up results: non-metastasis group, cervical lymph node metastasis group and pulmonary metastasis group. BRAFV600E mutation rates in different groups were compared (χ2 test). Results The BRAFV600E mutation rate was 55.22%(74/134) in 134 PTC patients. The mutation rates were not significantly different in the 3 metastasis subgroups for low-risk patients (n=46; χ2=2.39, P>0.05). In medium-risk patients (n=47), the mutation rate in neck lymph node metastasis group (16/19) was higher than that in pulmonary metastasis group (3/8) and non-metastasis group (25.00%, 5/20; χ2 values: 5.89 and 13.75, both P 0.05). In high risk patients (n=41), the mutation rate in neck lymph node metastasis group (85.00%, 17/20) was higher than that in the pulmonary metastasis group (5/13) and non-metastasis group (1/8; χ2 values: 7.68 and 13.08, both P 0.05). Conclusion The BRAFV600E mutation is closely related to neck lymph node metastasis after operation in middle- and high-risk patients with PTC, but it does not significantly increase the probabilities of neck lymph node metastasis in low-risk patients and pulmonary metastasis in low-, medium- and high-risk patients. Key words: Thyroid neoplasms; Neoplasms recurrence, local; Neoplasm metastasis; Proto-oncogene protein B-raf; Mutation

查看原文本刊更多论文

不同复发风险分层甲状腺乳头状癌甲状腺切除术后BRAFV600E突变与转移的关系

目的探讨V-raf鼠肉瘤病毒癌基因同源物B1 (BRAF)V600E突变与不同复发风险分层的乳头状甲状腺癌(PTC)甲状腺切除术后转移的关系。方法2014年3月至2017年9月，对134例PTC患者(男45例，女89例;回顾性分析在聊城市人民医院核医学科接受131I治疗并进行BRAFV600E突变检测的患者，年龄16 ~ 72岁。术中复发风险分为低、中、高危3个级别。每个复发风险组根据术后随访结果分为3个亚组:无转移组、宫颈淋巴结转移组和肺转移组。各组间BRAFV600E突变率比较(χ2检验)。结果134例PTC患者BRAFV600E基因突变率为55.22%(74/134)。低危患者3个转移亚组的突变率无显著差异(n=46;χ2 = 2.39,P > 0.05)。中危患者(n=47)中，颈淋巴结转移组的突变率(16/19)高于肺转移组(3/8)和非转移组(25.00%，5/20);χ2值:5.89、13.75,P均为0.05)。高危患者(n=41)中，颈淋巴结转移组的突变率(85.00%，17/20)高于肺转移组(5/13)和非转移组(1/8);χ2值:7.68、13.08,P均为0.05)。结论BRAFV600E基因突变与中、高危PTC术后颈淋巴结转移密切相关，但未显著增加低危患者颈淋巴结转移和低、中、高危患者肺转移的概率。关键词:甲状腺肿瘤;肿瘤复发，局部;肿瘤转移;原癌基因蛋白B-raf;突变

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

中华核医学与分子影像杂志核医学，分子影像

自引率

0.00%

发文量

5088

期刊介绍： Chinese Journal of Nuclear Medicine and Molecular Imaging (CJNMMI) was established in 1981, with the name of Chinese Journal of Nuclear Medicine, and renamed in 2012. As the specialized periodical in the domain of nuclear medicine in China, the aim of Chinese Journal of Nuclear Medicine and Molecular Imaging is to develop nuclear medicine sciences, push forward nuclear medicine education and basic construction, foster qualified personnel training and academic exchanges, and popularize related knowledge and raising public awareness. Topics of interest for Chinese Journal of Nuclear Medicine and Molecular Imaging include: -Research and commentary on nuclear medicine and molecular imaging with significant implications for disease diagnosis and treatment -Investigative studies of heart, brain imaging and tumor positioning -Perspectives and reviews on research topics that discuss the implications of findings from the basic science and clinical practice of nuclear medicine and molecular imaging - Nuclear medicine education and personnel training - Topics of interest for nuclear medicine and molecular imaging include subject coverage diseases such as cardiovascular diseases, cancer, Alzheimer’s disease, and Parkinson’s disease, and also radionuclide therapy, radiomics, molecular probes and related translational research.